Construction of nanometer cisplatin core-ferritin (NCC-F) and proteomic analysis of gastric cancer cell apoptosis induced with cisplatin released from the NCC-F

Journal of Proteomics

Volumn 75, Issue 11, 2012, Pages 3145-3157

  Ji, Xue Tao ^a   Huang, Lin ^a   Huang, He Qing ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Apoptosis of gastric cancer cells; Biomarker; Cisplatin (CDDP); Nanometer CDDP core PPF; Pig pancreas ferritin (PPF); Proteomics

Indexed keywords

BETA ACTIN; CALPAIN 1; CHAPERONIN CONTAINING TCP1; CISPLATIN; COMPLEMENT; FERRITIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BETA 1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; LACTOYLGLUTATHIONE LYASE; MESSENGER RNA; NANOMATERIAL; NANOMETER CISPLATIN CORE FERRITIN; PEROXIDASE; PEROXIREDOXIN 2; STATHMIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL METABOLISM; CONTROLLED STUDY; CYTOSKELETON; DRUG BINDING; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MASS SPECTROMETRY; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY; SPECTROPHOTOMETER; STOMACH CANCER; TRANSMISSION ELECTRON MICROSCOPY; TWO DIMENSIONAL ELECTROPHORESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG DELIVERY SYSTEMS; FERRITINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NANOPARTICLES; NEOPLASM PROTEINS; PROTEOMICS; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; SWINE;

SUIDAE;

EID: 84861681327     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.013     Document Type: Article

References (46)

1. Whitesides G.M. The 'right' size in nanobiotechnology. Nat Biotechnol 2003, 21:1161-1165.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
3. Jain K.K. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008, 17:89-101.
4. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
5. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
6. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43.
7. Pinzani V., Bressolle F., Haug I.J. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994, 35:1-9.
8. Kopelman J., Budnic A.S., Sessions R.S., Kramer M.B., Wong G.Y. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988, 98:858-864.
9. Orino K., Watanabe K. Molecular, physiological and clinical aspects of the iron storage protein ferritin. Vet J 2008, 178:191-201.
10. Uchidaa M., Kanga S., Reichhardta C., Harlen K., Douglas T. The ferritin superfamily: supramolecular templates for materials synthesis. Biochim Biophys Acta 2010, 1800:834-845.
11. Simsek E., Kilic M.A. Magic ferritin: a novel chemotherapeutic encapsulation bullet. J Magn Magn Mater 2005, 293:509-513.
12. Frame J.W.B., Zhao Z., Lee M.L., Watt G.D. Molecular entrapment of small molecules within the interior of horse spleen ferritin. Arch Biochem Biophys 1994, 309:178-183.
13. Yang Z., Wang X., Diao H., Zhang J., Li H., Sun H., et al. Encapsulation of platinum anticancer drugs by apoferritin. Chem Commun 2007, 33:3453-3455.
14. Bretscher M.S., Thomson J.N. Distribution of ferritin receptors and coated pits on giant Hela cells. EMBO J 1983, 2:599-603.
15. Kong B., Huang H.Q., Lin Q.M., Kim W.S., Cai Z., Cao T.M., et al. Purification, electrophoretic behavior, and kinetics of iron release of liver ferritin of Dasyatis akajei. J Protein Chem 2003, 22:61-70.
16. Huang L., Lin Z., Lin Q., Luo L.Z., Huang H.Q. Subunit characteristics of pig pancreas ferritin revealed by MALDI-TOF MS and RP-HPLC. Chem Res Chin Univ 2008, 24:550-556.
17. Stefanini S., Cavallo S., Wang C.Q., Tataseo P., Vecchini P., Giartosio A., et al. Thermal stability of horse spleen apoferritin and human recombinant H apoferritin. Arch Biochem Biophys 1996, 325:58-64.
18. Huang Q.Y., Huang H.Q. Differential expression profile of membrane proteins in zebrafish (Danio rerio) brain exposed to methyl parathion. Proteomics 2011, 11:3743-3756.
19. Huang Q.Y., Fang C.W., Huang H.Q. Alteration of heart tissue protein profiles in acute cadmium-treated scallops Patinopecten yessoensis. Arch Environ Contam Toxicol 2011, 60:90-98.
20. Huang Q.Y., Huang L., Huang H.Q. Proteomic analysis of methyl parathion-responsive proteins in zebrafish (Danio rerio) brain. Comp Biochem Physiol C 2011, 153:67-74.
21. Swift J., Wehbi W.A., Kelly B.D., Fu X.S., Saven J.G., Dmochowski I.J. Design of functional ferritin-like proteins with hydrophobic cavities. J Am Chem Soc 2006, 128:6611-6619.
22. Andrews S.C. The Ferritin-like superfamily: evolution of the biological iron storeman from a rubrerythrin-like ancestor. Biochim Biophys Acta 2010, 1800:691-705.
23. Huang Q., Huang H.Q. Alterations of protein profiles in zebrafish liver cells exposed to methyl parathion: a membrane proteomics approach. Chemosphere 2012, 87:68-73.
24. Fan J., Yin J.J., Ning B., Wu X.C., Hu Y., Ferrari M., et al. Direct evidence for catalase and peroxidase activities of ferritin-platinum nanoparticles. Biomaterials 2011, 32:1611-1618.
25. Gibaud S., Gaia A., Astier A. Slow-release melarsoprol microparticles. Int J Pharm 2002, 243:161-166.
26. Pottiez G., Duban-Deweer S., Deracinois B., Gosselet F., Camoin L., Hachani J., et al. A differential proteomic approach identifies structural and functional components that contribute to the differentiation of brain capillary endothelial cells. J Proteomics 2011, 75:628-641.
27. Malard V., Charfan L., Roussi S., Darolles C., Sage N., Gaillard J.C., Armengaud J. Analytical constraints for the analysis of human cell line secretomes by shotgun proteomics. J Proteomics. 2012, 75:1043-1054.
28. Cao W., Ma D., Kapur A., Patankar M.S., Ma Y., Li L. RT-SVR+q: a strategy for post-mascot analysis using retention time and q value metric to improve peptide and protein identifications. J Proteomics 2011, 75:480-490.
29. Thornalley P.J. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003, 31:1343-1348.
30. Thornalley P.J. The glyoxalase system in health and disease. Mol Aspects Med 1993, 14:287-371.
31. Marklund U., Larsson N., Gradin H.M., Brattsand G., Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 1996, 15:5290-5298.
32. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002, 14:18-24.
33. Wood Z.A., Schröder E., Harris J.R., Leslie B.P. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003, 28:32-40.
34. Hofmann B., Hecht H.J., Flohé L. Peroxiredoxins. Biol Chem 2002, 383:347-364.
35. Neumann C.A., Fang Q. Are peroxiredoxins tumor suppressors?. Curr Opin Pharmacol 2007, 7:375-380.
36. Kim H., Lee T.H., Park E.S., Jae M.S., Suh J.M., Park S.J., et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced. Apoptosis Thyroid Cells 2000, 275:18266-18270.
37. Zhang B., Wang Y., Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009, 286:154-160.
38. Michelotti E.F., Michelotti G.A., Aronsohn A.I., Levens D., Aronsohn A.I. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 1996, 16:2350-2360.
39. Tomonaga T., Levens D. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator. J Biol Chem 1995, 270:4875-4881.
40. Carpenter B., McKay M., Dundas S.R., Lawrie L.C., Murray G.I. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006, 95:921-927.
41. White M.C., Gao R., Xu W., Santi M.M., LIM J.G., Hazra T.K., et al. Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCd to mitochondria in spinocerebellar ataxia 10. PLoS Genet 2010, 6:1-12.
42. Winn S.I., Watson H.C., Harkins R.N., Fothergill L.A. Structure and activity of phosphoglycerate mutase. Philos Trans R Soc B 1981, 293:121-130.
43. Petrak J., Lvanek R., Toman O., Cmejta R., Cemejlova J., Vyoral D., et al. Déjà vu in proteomics: a hit parade of repeatedly identified differentially expression proteins. Proteomics 2008, 8:1744-1749.
44. Wang P., Bouwman F.G., Mariman E.C.M. Generally detected proteins in comparative proteomics-a matter of cellular stress response?. Proteomics 2009, 9:2955-2966.
45. Chen H.B., Huang H.Q. Proteomic analysis of methyl parathion-responsive proteins in Sparus latus liver. Fish Shellfish Immunol 2011, 30:800-806.
46. Huang L., Huang Q.Y., Chen H.B., Huang F.S., Huang H.Q. Differential proteins of the optic ganglion in Octopus vulgaris under methanol stress revealed using proteomics. Appl Biochem Biotechnol 2011, 165:978-988.